Cargando…
Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer
Pathogenic variants (PVs) in multiple genes are known to increase the risk of early-onset renal cancer (eoRC). However, many eoRC patients lack PVs in RC-specific genes; thus, their genetic risk remains undefined. Here, we determine if PVs in DNA damage response and repair (DDRR) genes are enriched...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419503/ https://www.ncbi.nlm.nih.gov/pubmed/32782288 http://dx.doi.org/10.1038/s41598-020-70449-5 |
_version_ | 1783569897906765824 |
---|---|
author | Hartman, Tiffiney R. Demidova, Elena V. Lesh, Randy W. Hoang, Lily Richardson, Marcy Forman, Andrea Kessler, Lisa Speare, Virginia Golemis, Erica A. Hall, Michael J. Daly, Mary B. Arora, Sanjeevani |
author_facet | Hartman, Tiffiney R. Demidova, Elena V. Lesh, Randy W. Hoang, Lily Richardson, Marcy Forman, Andrea Kessler, Lisa Speare, Virginia Golemis, Erica A. Hall, Michael J. Daly, Mary B. Arora, Sanjeevani |
author_sort | Hartman, Tiffiney R. |
collection | PubMed |
description | Pathogenic variants (PVs) in multiple genes are known to increase the risk of early-onset renal cancer (eoRC). However, many eoRC patients lack PVs in RC-specific genes; thus, their genetic risk remains undefined. Here, we determine if PVs in DNA damage response and repair (DDRR) genes are enriched in eoRC patients undergoing cancer risk assessment. Retrospective review of de-identified results from 844 eoRC patients, undergoing testing with a multi-gene panel, for a variety of indications, by Ambry Genetics. PVs in cancer-risk genes were identified in 12.8% of patients—with 3.7% in RC-specific, and 8.55% in DDRR genes. DDRR gene PVs were most commonly identified in CHEK2, BRCA1, BRCA2, and ATM. Among the 2.1% of patients with a BRCA1 or BRCA2 PV, < 50% reported a personal history of hereditary breast or ovarian-associated cancer. No association between age of RC diagnosis and prevalence of PVs in RC-specific or DDRR genes was observed. Additionally, 57.9% patients reported at least one additional cancer; breast cancer being the most common (40.1% of females, 2.5% of males). Multi-gene testing including DDRR genes may provide a more comprehensive risk assessment in eoRC patients. Further validation is needed to characterize the association with eoRC. |
format | Online Article Text |
id | pubmed-7419503 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-74195032020-08-13 Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer Hartman, Tiffiney R. Demidova, Elena V. Lesh, Randy W. Hoang, Lily Richardson, Marcy Forman, Andrea Kessler, Lisa Speare, Virginia Golemis, Erica A. Hall, Michael J. Daly, Mary B. Arora, Sanjeevani Sci Rep Article Pathogenic variants (PVs) in multiple genes are known to increase the risk of early-onset renal cancer (eoRC). However, many eoRC patients lack PVs in RC-specific genes; thus, their genetic risk remains undefined. Here, we determine if PVs in DNA damage response and repair (DDRR) genes are enriched in eoRC patients undergoing cancer risk assessment. Retrospective review of de-identified results from 844 eoRC patients, undergoing testing with a multi-gene panel, for a variety of indications, by Ambry Genetics. PVs in cancer-risk genes were identified in 12.8% of patients—with 3.7% in RC-specific, and 8.55% in DDRR genes. DDRR gene PVs were most commonly identified in CHEK2, BRCA1, BRCA2, and ATM. Among the 2.1% of patients with a BRCA1 or BRCA2 PV, < 50% reported a personal history of hereditary breast or ovarian-associated cancer. No association between age of RC diagnosis and prevalence of PVs in RC-specific or DDRR genes was observed. Additionally, 57.9% patients reported at least one additional cancer; breast cancer being the most common (40.1% of females, 2.5% of males). Multi-gene testing including DDRR genes may provide a more comprehensive risk assessment in eoRC patients. Further validation is needed to characterize the association with eoRC. Nature Publishing Group UK 2020-08-11 /pmc/articles/PMC7419503/ /pubmed/32782288 http://dx.doi.org/10.1038/s41598-020-70449-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Hartman, Tiffiney R. Demidova, Elena V. Lesh, Randy W. Hoang, Lily Richardson, Marcy Forman, Andrea Kessler, Lisa Speare, Virginia Golemis, Erica A. Hall, Michael J. Daly, Mary B. Arora, Sanjeevani Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer |
title | Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer |
title_full | Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer |
title_fullStr | Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer |
title_full_unstemmed | Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer |
title_short | Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer |
title_sort | prevalence of pathogenic variants in dna damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419503/ https://www.ncbi.nlm.nih.gov/pubmed/32782288 http://dx.doi.org/10.1038/s41598-020-70449-5 |
work_keys_str_mv | AT hartmantiffineyr prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer AT demidovaelenav prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer AT leshrandyw prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer AT hoanglily prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer AT richardsonmarcy prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer AT formanandrea prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer AT kesslerlisa prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer AT spearevirginia prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer AT golemisericaa prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer AT hallmichaelj prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer AT dalymaryb prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer AT arorasanjeevani prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer |